Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic ...
Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS ...
Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...
Silexion Therapeutics (SLXN) announced positive data from orthotopic pancreatic cancer models demonstrating that subcutaneously administered ...
Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced ...
Silexion Therapeutics completes initial study of SIL-204 in pancreatic cancer models, assessing tumor growth and metastasis. Results expected in March 2025. Silexion Therapeutics Corp. announced ...
Silexion Therapeutics Corp. announced promising results from preclinical studies of its RNA interference therapy, SIL204, for KRAS-driven pancreatic cancer. The research, conducted in orthotopic ...
The Company anticipates sharing initial results from the study in March 2025. These results will inform Silexion's development strategy for SIL-204. This press release contains forward-looking ...
Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback